Latest news for Medinotec (OTC:MDNC) Stock

Medinotec Inc is a Dominant company in tracheal non-occlusive airway dilation technology, specializing in medical device design, manufacture, and distribution worldwide. The Company has two operating segments, inside the United States and outside the United States. The Company generates revenues through two distinct sources which include sales of self-manufactured high-quality medical devices developed through extensive research and development, and distribution of finished products for other principals worldwide, typically within exclusive territories granted by these principals.

Medinotec Inc

<p>Wolfe Research  analyst Darrin Peller   downgrades BILL Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BILL#NYSE">BILL</a>) from Outperform to Peer Perform.</p>


News

Downgrades

Analyst Ratings

BILL

Wolfe Research Downgrades BILL Holdings to Peer Perform

<p>Analysts' ratings for Dana (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DAN#NYSE">DAN</a>) over the last quarter vary from bullish to bearish, as provided by 4 analysts.</p>
<p>The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $13.5, along with a high estimate of $17.00 and a low estimate of $12.00. Experiencing a 5.26% decline, the current average is now lower than the previous average price target of $14.25. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722539389_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>A clear picture of Dana's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$13.00</td>
<td>$12.00</td>
</tr>
<tr>
<td>Ryan Brinkman</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$17.00</td>
<td>$18.00</td>
</tr>
<tr>
<td>Colin Langan</td>
<td>UBS</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$12.00</td>
<td>$14.00</td>
</tr>
<tr>
<td>Colin Langan</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$12.00</td>
<td>$13.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Dana. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Dana compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Dana's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Dana's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/DAN/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Dana analyst ratings.</strong></a></p>
<p>If you are interested in following small-cap stock news and performance <a href="https://www.benzinga.com/news/small-cap">you can start by tracking it here</a>.</p>
<h2>Delving into Dana's Background</h2>
<p>Dana Inc is engaged in the designing and manufacturing of efficient propulsion and energy-management solutions that power vehicles and machines in all mobility markets across the globe. The company has four operating segments: Light Vehicles, Power Technologies, Commercial Vehicle, and Off-Highway. The Light Vehicles segment generates the majority portion of revenue by providing products to support light vehicle OEMs. Its products are designed for light trucks, SUVs, CUVs, vans, and passenger cars.</p>
<h3>Dana's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.</p>
<p><strong>Revenue Growth:</strong> Dana's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of <strong>3.44%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Consumer Discretionary sector.</p>
<p><strong>Net Margin:</strong> Dana's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>0.11%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Dana's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>0.19%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>0.04%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of <strong>1.91</strong>, caution is advised due to increased financial risk.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Breaking Down Dana: 4 Analysts Share Their Views

<p>Summit Insights Group  analyst Kinngai Chan   downgrades Western Digital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) from Buy to Hold.</p>


Summit Insights Group Downgrades Western Digital to Hold

<p>8 analysts have expressed a variety of opinions on Genmab (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GMAB#NASDAQ">GMAB</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">8</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have set 12-month price targets for Genmab, revealing an average target of $50.0, a high estimate of $53.00, and a low estimate of $47.00. This upward trend is apparent, with the current average reflecting a 1.01% increase from the previous average price target of $49.50.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722539288_0.png" alt="price target chart" /></p>
<h2>Exploring Analyst Ratings: An In-Depth Overview</h2>
<p>The standing of Genmab among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Kaveri Pohlman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$47.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Asthika Goonewardene</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$53.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
<tr>
<td>Raghuram Selvaraju</td>
<td>HC Wainwright &amp; Co.</td>
<td>Maintains</td>
<td>Buy</td>
<td>$50.00</td>
<td>$50.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Genmab. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Genmab compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts set price targets as an estimate of a stock's future value. Comparing the current and prior price targets provides insight into how analysts' expectations have changed over time. This information can be valuable for investors seeking to understand consensus views on the stock's potential future performance.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Genmab's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GMAB/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Genmab analyst ratings.</strong></a></p>
<h2>All You Need to Know About Genmab</h2>
<p>Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson &amp; Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson &amp; Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.</p>
<h3>Financial Insights: Genmab</h3>
<p><strong>Market Capitalization Analysis:</strong> Below industry benchmarks, the company's market capitalization reflects a smaller scale relative to peers. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Genmab's revenue growth over a period of 3 months has been noteworthy. As of 31 March, 2024, the company achieved a revenue growth rate of approximately <strong>46.19%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Health Care sector.</p>
<p><strong>Net Margin:</strong> Genmab's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>31.98%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Genmab's ROE excels beyond industry benchmarks, reaching <strong>4.13%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>3.68%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.03</strong>.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


GMAB

What 8 Analyst Ratings Have To Say About Genmab

<p>The war has already started.</p>
<p>You probably missed the first shots being fired.</p>
<p>I know I did.</p>
<p>I think everyone missed the first skirmishes.</p>
<p>At first, this conflict was so unexpected that it seemed like it could never even rise to the level of David and Goliath.</p>
<p>At the start of this conflict, Goliath was too big and powerful, and David was too technologically backward and behind.</p>
<p>When China first began developing a semiconductor industry in the 1990s, no one gave them much of a chance.</p>
<p>The United States dominated the global semiconductor industry, especially in high-end semiconductor technology.</p>
<p>We underestimated China&#8217;s desire, drive, and ruthless determination to win the race for technological supremacy.</p>
<p>We also underestimated China&#8217;s dedication to the idea of winning at all costs.</p>
<p>If they could not develop and build a given technology themselves, they would have no problem stealing it from the West.</p>
<p>The drive and dedication of the Chinese people, together with some well-executed intellectual property theft, have made the race closer than anyone expected back when those almost silent first shots were fired.</p>
<p>Winning the chip race does not seem all that important until you understand where we are on the technology curve and what it means to be the first to the finish line.</p>
<p>The company that wins the high-end chip race wins the AI race, and that leads to victory in quantum computing.</p>
<p>The nation or coalition that dominates those parts of the technology spectrum will dominate the world and the global economy.</p>
<p>They would have absolute control of space.</p>
<p>That nation would have an enormous edge in autonomous warfare, including drones and robotic attack forces.</p>
<p>It would have more advanced weapons systems.</p>
<p>Its influence on global economies and markets would be enormous.</p>
<p>The winner of this race will dominate the discovery and production of drugs and life-saving medical devices.</p>
<p>Their cyberwarfare and cybersecurity programs will be dominant.</p>
<p>The winner will control so many facets of life that they will become the envy of both Pinky and the Brain as they finally achieve the objective of obtaining world domination.</p>
<p>This war is not in the headlines much, but it may be the most important conflict in modern history.</p>
<p><strong>What can we do about it?</strong></p>
<p>The answer is not very much, with the exception of those readers who toil in the tech industry and are feverishly scrambling to win the race.</p>
<p>The battle will be won by technocrats and (unfortunately) politicians along with the assistance of the people who finance innovation and technology.</p>
<p>What we can do is recognize that, even if it is not on the front page of the New York Times or Washington Examiner (see how I threaded the political needle there?), it is the highest priority both at home and abroad.</p>
<p>Trillions of dollars will be spent on this war.</p>
<p>That is going to lead to massive profits for companies in the semiconductor industry and suppliers to those industries.</p>
<p>Chip manufacturers, semiconductor packaging and test equipment companies, and raw material companies are going to see enormous benefits.</p>
<p>Much like Quint, Hooper, and Brody needed a bigger boat, we will need a lot more data centers to win this war.</p>
<p>Bringing the semiconductor and related industries back to the United States will also involve the construction of an enormous number of new facilities.</p>
<p>This opens opportunities for REITs, construction companies, fiber optic cable manufacturers, and other companies that will supply the material to build the infrastructure and operate the centers.</p>
<p>The battle for semiconductor supremacy and the leadership role in Artificial Intelligence will require enormous energy.</p>
<p>There is no need to involve politics in this decision. Winning this war will require all forms of energy. Fossil fuels, renewables, and nuclear energy companies will also be in massive demand for this conflict.</p>
<p>It is critical for the United States and the West to at least fight China to a draw in this conflict. A victory would be best, but the mutually assured destruction of a draw would suffice for survival and prosperity purposes.</p>
<p>Under either scenario, massive, almost unimaginable amounts of money will be spent, and the profits will go to patient and aggressive investors who seize opportunities when they are available at the right price.</p>
<p>Traders will miss this stunning opportunity if they insist on focusing on the short term.</p>
<p>There are two ways to play the profiteering potential of the semiconductor war.</p>
<p>One is to wait for sectors that can be expected to see waves of cash from the conflict to be out of favor and create the opportunity to buy companies at sale prices.</p>
<p>Today, that opportunity exists in the natural gas sector of the energy industry. The demand for natural gas to power the war effort will be enormous, as will the cash generated by the owners of assets like pipelines that transport energy from one place to another.</p>
<p>Certain real estate assets that will be huge beneficiaries of the demand for data centers and factory space are also cheap.</p>
<p>When you step away from the narrow spotlight on the industry leaders, you will see that several mission-critical semiconductor companies are also trading at bargain basement prices right now.</p>
<p>The modest selloff in semiconductor equipment and material stocks would also create a handful of bargains, with the potential for returns of several times current stock prices.</p>
<p>The war is not going to happen.</p>
<p>It is happening now.</p>
<p>Privateers have always gotten rich off wars.</p>
<p>The potential profits from this one will be the largest in modern history.</p>
<p>If you want more of my research or want to see the stock, i picked that jumped 30% in 1 month after I recommended it this year, <a href="https://www.benzinga.com/premium/ideas/yield-report-sales-page/?t=yiyi1spjoreyr2&amp;utm_source=RD-0801"><strong>Click Here</strong></a></p>
<p><em>Photo: asharkyu/Shutterstock.com</em></p>


Opinion

Trading Ideas

The Next Great "Tech War" Has Already Started - And Here's Who's Winning

<p>Across the recent three months, 12 analysts have shared their insights on Glaukos (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GKOS#NYSE">GKOS</a>), expressing a variety of opinions spanning from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">7</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $132.17, a high estimate of $145.00, and a low estimate of $120.00. This upward trend is apparent, with the current average reflecting a 13.86% increase from the previous average price target of $116.08.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722539236_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>A clear picture of Glaukos's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$140.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$135.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$145.00</td>
<td>$141.00</td>
</tr>
<tr>
<td>David Saxon</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$137.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Samuel Brodovsky</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$141.00</td>
<td>$125.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$131.00</td>
<td>$112.00</td>
</tr>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$120.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Neutral</td>
<td>$132.00</td>
<td>$130.00</td>
</tr>
<tr>
<td>Thomas Stephan</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$120.00</td>
<td>$110.00</td>
</tr>
<tr>
<td>Joanne Wuensch</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$130.00</td>
<td>$120.00</td>
</tr>
<tr>
<td>Michael Sarcone</td>
<td>Jefferies</td>
<td>Raises</td>
<td>Buy</td>
<td>$125.00</td>
<td>$84.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Glaukos. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Glaukos compared to the broader market.</li>
<li><strong>Price Targets:</strong> Understanding forecasts, analysts offer estimates for Glaukos's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Glaukos's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GKOS/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Glaukos analyst ratings.</strong></a></p>
<h2>All You Need to Know About Glaukos</h2>
<p>Glaukos Corp is an ophthalmic medical technology company focused on the development and commercialization of breakthrough products and procedures designed to transform the treatment of glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma. Its product pipeline also consists of an iStent SA trabecular micro-bypass system, a two-stent product that is slightly wider than the iStent Inject and uses a different auto-injection inserter designed for use in a standalone procedure.</p>
<h3>Glaukos: Delving into Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Glaukos's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of <strong>15.86%</strong>. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<p><strong>Net Margin:</strong> Glaukos's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of <strong>-47.7%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Glaukos's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>-8.95%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of <strong>-4.36%,</strong> the company may need to address challenges in generating satisfactory returns from its assets.</p>
<p><strong>Debt Management:</strong> Glaukos's debt-to-equity ratio surpasses industry norms, standing at <strong>0.85</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Basics of Analyst Ratings</h2>
<p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.</p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


GKOS

Glaukos Stock: A Deep Dive Into Analyst Perspectives (12 Ratings)

Macro Notification

General

iShares MSCI Israel Capped Investable Market Index Fund

iShares MSCI Turkey Investable Market Index Fund

Turkey's Erdogan And Biden Discuss Bilateral Ties, Gaza War, Prisoner Swap In Phone Call; Erdogan Told Biden Israel Does Not Want Ceasefire, Killing Of Hamas Chief Harmed Ceasefire Efforts, And Israel Is Trying To Spread Conflict To Wider Region, Turkish Presidency Says

<p>Allstate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ALL#NYSE">ALL</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.</p>
<p>The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $194.62, along with a high estimate of $226.00 and a low estimate of $153.00. Observing a 1.63% increase, the current average has risen from the previous average price target of $191.50. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722539228_0.png" alt="price target chart" /></p>
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
<p>A comprehensive examination of how financial experts perceive Allstate is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Joshua Shanker</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$226.00</td>
<td>$213.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$199.00</td>
<td>$197.00</td>
</tr>
<tr>
<td>Michael Zaremski</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$191.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Jimmy Bhullar</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$193.00</td>
</tr>
<tr>
<td>Michael Phillips</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$194.00</td>
<td>$194.00</td>
</tr>
<tr>
<td>Meyer Shields</td>
<td>Keefe, Bruyette &amp; Woods</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$194.00</td>
<td>$194.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$153.00</td>
<td>$146.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Allstate. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Allstate compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts explore the dynamics of price targets, providing estimates for the future value of Allstate's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Allstate's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/ALL/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Allstate analyst ratings.</strong></a></p>
<h2>Delving into Allstate's Background</h2>
<p>Allstate is one of the largest US property and casualty insurers in the US. Personal auto represents the largest percentage of revenue, but the company offers homeowners insurance and other insurance products. Allstate products are sold in North America primarily by about 10,000 company agencies.</p>
<h3>Key Indicators: Allstate's Financial Health</h3>
<p><strong>Market Capitalization Analysis:</strong> With an elevated market capitalization, the company stands out above industry averages, showcasing substantial size and market acknowledgment.</p>
<p><strong>Revenue Growth:</strong> Allstate displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately <strong>10.68%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> The company's net margin is below industry benchmarks, signaling potential difficulties in achieving strong profitability. With a net margin of <strong>7.79%,</strong> the company may need to address challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Allstate's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of <strong>7.34%,</strong> the company showcases efficient use of equity capital and strong financial health.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>1.14%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Allstate's debt-to-equity ratio surpasses industry norms, standing at <strong>0.48</strong>. This suggests the company carries a substantial amount of debt, posing potential financial challenges.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Demystifying Allstate: Insights From 8 Analyst Reviews

<p>Deep-pocketed investors have adopted a bullish approach towards ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>), and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today. The identity of these investors remains unknown, but such a substantial move in ASML usually suggests something big is about to happen.</p>
<p>We gleaned this information from our observations today when Benzinga's options scanner highlighted 40 extraordinary options activities for ASML Holding. This level of activity is out of the ordinary.</p>
<p>The general mood among these heavyweight investors is divided, with 40% leaning bullish and 40% bearish. Among these notable options, 18 are puts, totaling $1,105,186, and 22 are calls, amounting to $2,490,472.</p>
<h3>What's The Price Target?</h3>
<p>Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $360.0 to $1070.0 for ASML Holding during the past quarter. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for ASML Holding's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of ASML Holding's whale trades within a strike price range from $360.0 to $1070.0 in the last 30 days. </p>
<h3>ASML Holding 30-Day Option Volume &amp; Interest Snapshot</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722539184_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>ASML</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$59.2</td>
<td>$55.9</td>
<td>$58.8</td>
<td>$960.00</td>
<td>$441.0K</td>
<td style="text-align: right;">28</td>
<td style="text-align: right;">75</td>
</tr>
<tr>
<td>ASML</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$42.5</td>
<td>$41.6</td>
<td>$42.5</td>
<td>$920.00</td>
<td>$425.0K</td>
<td style="text-align: right;">141</td>
<td style="text-align: right;">105</td>
</tr>
<tr>
<td>ASML</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>10/18/24</td>
<td>$42.0</td>
<td>$41.4</td>
<td>$41.4</td>
<td>$950.00</td>
<td>$380.8K</td>
<td style="text-align: right;">456</td>
<td style="text-align: right;">213</td>
</tr>
<tr>
<td>ASML</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>09/20/24</td>
<td>$121.9</td>
<td>$119.8</td>
<td>$121.9</td>
<td>$820.00</td>
<td>$182.8K</td>
<td style="text-align: right;">30</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>ASML</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$87.1</td>
<td>$85.6</td>
<td>$85.6</td>
<td>$930.00</td>
<td>$128.4K</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">15</td>
</tr>
</tbody>
</table>
</p>
<h3>About ASML Holding</h3>
<p>ASML is the leader in photolithography systems used in the manufacturing of semiconductors. Photolithography is the process in which a light source is used to expose circuit patterns from a photo mask onto a semiconductor wafer. The latest technological advances in this segment allow chipmakers to continually increase the number of transistors on the same area of silicon, with lithography historically representing a high portion of the cost of making cutting-edge chips. ASML outsources the manufacturing of most of its parts, acting like an assembler. ASML's main clients are TSMC, Samsung, and Intel.</p>
<p>Following our analysis of the options activities associated with ASML Holding, we pivot to a closer look at the company's own performance.</p>
<h3>Present Market Standing of ASML Holding</h3>
<ul>
<li>Trading volume stands at 1,033,610, with ASML's price down by -1.51%, positioned at $922.56.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 76 days.</li>
</ul>
<p>Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for ASML Holding with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.</p>


Options

Markets

ASML

Spotlight on ASML Holding: Analyzing the Surge in Options Activity

<p>Whales with a lot of money to spend have taken a noticeably bearish stance on <strong>American Express</strong>.</p>
<p>Looking at options history for American Express (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXP#NYSE">AXP</a>) we detected 8 trades.</p>
<p>If we consider the specifics of each trade, it is accurate to state that 12% of the investors opened trades with bullish expectations and 50% with bearish.</p>
<p>From the overall spotted trades, 5 are puts, for a total amount of $406,626 and 3, calls, for a total amount of $107,351.</p>
<h3>Projected Price Targets</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $245.0 to $270.0 for American Express over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>In today's trading context, the average open interest for options of American Express stands at 1066.2, with a total volume reaching 4,967.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in American Express, situated within the strike price corridor from $245.0 to $270.0, throughout the last 30 days.</p>
<h3>American Express Call and Put Volume: 30-Day Overview</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722539179_0.png" alt="Options Call Chart" /></p>
<h3>Noteworthy Options Activity:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th><strong>Open Interest</strong></th>
<th><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>AXP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/16/24</td>
<td>$4.85</td>
<td>$4.7</td>
<td>$4.78</td>
<td>$250.00</td>
<td>$186.3K</td>
<td>1.8K</td>
<td>472</td>
</tr>
<tr>
<td>AXP</td>
<td>PUT</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>08/16/24</td>
<td>$2.81</td>
<td>$2.68</td>
<td>$2.75</td>
<td>$245.00</td>
<td>$107.4K</td>
<td>1.3K</td>
<td>1.1K</td>
</tr>
<tr>
<td>AXP</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$4.55</td>
<td>$4.5</td>
<td>$4.55</td>
<td>$250.00</td>
<td>$55.5K</td>
<td>1.8K</td>
<td>1.5K</td>
</tr>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$19.5</td>
<td>$18.75</td>
<td>$19.5</td>
<td>$260.00</td>
<td>$38.9K</td>
<td>1.2K</td>
<td>41</td>
</tr>
<tr>
<td>AXP</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$18.25</td>
<td>$17.75</td>
<td>$17.75</td>
<td>$260.00</td>
<td>$37.2K</td>
<td>1.2K</td>
<td>74</td>
</tr>
</tbody>
</table>
</p>
<h3>About American Express</h3>
<p>American Express is a global financial institution, operating in about 130 countries, that provides consumers and businesses charge and credit card payment products. The company also operates a highly profitable merchant payment network. Since 2018, it has operated in three segments: global consumer services, global commercial services, and global merchant and network services. In addition to payment products, the company's commercial business offers expense management tools, consulting services, and business loans.</p>
<p>In light of the recent options history for American Express, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Current Position of American Express</h3>
<ul>
<li>Trading volume stands at 1,767,722, with AXP's price down by -2.31%, positioned at $247.2.</li>
<li>RSI indicators show the stock to be may be approaching overbought.</li>
<li>Earnings announcement expected in 78 days.</li>
</ul>
<h3>Professional Analyst Ratings for American Express</h3>
<p>5 market experts have recently issued ratings for this stock, with a consensus target price of $252.6.</p>
<ul>
<li>An analyst from Monness, Crespi, Hardt persists with their Buy rating on American Express, maintaining a target price of $265. </li>
<li>An analyst from Barclays persists with their Equal-Weight rating on American Express, maintaining a target price of $223. </li>
<li>Consistent in their evaluation, an analyst from Jefferies keeps a Hold rating on American Express with a target price of $235. </li>
<li>Maintaining their stance, an analyst from Keefe, Bruyette &amp; Woods continues to hold a Outperform rating for American Express, targeting a price of $280. </li>
<li>In a cautious move, an analyst from Compass Point downgraded its rating to Neutral, setting a price target of $260. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for American Express, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


Behind the Scenes of American Express's Latest Options Trends

<p>Investors with a lot of money to spend have taken a bullish stance on <strong>Fair Isaac</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FICO#NYSE">FICO</a>).</p>
<p>And retail traders should know.</p>
<p>We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.</p>
<p>Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with FICO, it often means somebody knows something is about to happen.</p>
<p>So how do we know what these investors just did? </p>
<p>Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 10 uncommon options trades for Fair Isaac.</p>
<p>This isn't normal.</p>
<p>The overall sentiment of these big-money traders is split between 50% bullish and 40%, bearish.</p>
<p>Out of all of the special options we uncovered, 3 are puts, for a total amount of $88,960, and 7 are calls, for a total amount of $324,042.</p>
<h3>Expected Price Movements</h3>
<p>Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $970.0 to $1930.0 for Fair Isaac over the recent three months. </p>
<h3>Volume &amp; Open Interest Trends</h3>
<p>Looking at the volume and open interest is a powerful move while trading options. This data can help you track the liquidity and interest for Fair Isaac's options for a given strike price. Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Fair Isaac's whale trades within a strike price range from $970.0 to $1930.0 in the last 30 days. </p>
<h3>Fair Isaac Option Volume And Open Interest Over Last 30 Days</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722539174_0.png" alt="Options Call Chart" /></p>
<h3>Largest Options Trades Observed:</h3>
<p>
<table>
<thead>
<tr>
<th><strong>Symbol</strong></th>
<th><strong>PUT/CALL</strong></th>
<th><strong>Trade Type</strong></th>
<th><strong>Sentiment</strong></th>
<th><strong>Exp. Date</strong></th>
<th><strong>Ask</strong></th>
<th><strong>Bid</strong></th>
<th><strong>Price</strong></th>
<th><strong>Strike Price</strong></th>
<th><strong>Total Trade Price</strong></th>
<th style="text-align: right;"><strong>Open Interest</strong></th>
<th style="text-align: right;"><strong>Volume</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$700.0</td>
<td>$690.8</td>
<td>$691.51</td>
<td>$970.00</td>
<td>$69.1K</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
</tr>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>08/16/24</td>
<td>$65.0</td>
<td>$57.5</td>
<td>$60.05</td>
<td>$1590.00</td>
<td>$60.0K</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$80.0</td>
<td>$76.0</td>
<td>$80.0</td>
<td>$1530.00</td>
<td>$56.0K</td>
<td style="text-align: right;">10</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$90.0</td>
<td>$88.3</td>
<td>$90.0</td>
<td>$1590.00</td>
<td>$45.0K</td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">15</td>
</tr>
<tr>
<td>FICO</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$337.2</td>
<td>$333.0</td>
<td>$337.2</td>
<td>$1340.00</td>
<td>$33.7K</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
</p>
<h3>About Fair Isaac</h3>
<p>Founded in 1956, Fair Isaac Corporation is a leading applied analytics company. Fair Isaac is primarily known for its FICO credit scores, which is a widely used industry benchmark to determine the creditworthiness of an individual consumer. The firm's credit scores business accounts for most of the firm's profits and consists of business-to-business and business-to-consumer services. In addition to scores, Fair Isaac also sells software primarily to financial institutions for areas such as analytics, decision-making, customer workflows, and fraud.</p>
<p>In light of the recent options history for Fair Isaac, it's now appropriate to focus on the company itself. We aim to explore its current performance.</p>
<h3>Fair Isaac's Current Market Status</h3>
<ul>
<li>With a trading volume of 178,719, the price of FICO is down by 0.0%, reaching $1600.0.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 97 days from now.</li>
</ul>
<h3>Expert Opinions on Fair Isaac</h3>
<p>In the last month, 3 experts released ratings on this stock with an average target price of $1641.6666666666667.</p>
<ul>
<li>An analyst from RBC Capital has decided to maintain their Sector Perform rating on Fair Isaac, which currently sits at a price target of $1500. </li>
<li>An analyst from Baird has decided to maintain their Neutral rating on Fair Isaac, which currently sits at a price target of $1700. </li>
<li>In a cautious move, an analyst from Wolfe Research downgraded its rating to Outperform, setting a price target of $1725. </li>
</ul>
<p>Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.</p>
<p>If you want to stay updated on the latest options trades for Fair Isaac, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.</p>


FICO

Behind the Scenes of Fair Isaac's Latest Options Trends

<p>Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Trane Technologies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TT#NYSE">TT</a>) in the last three months.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">2</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Trane Technologies and provided 12-month price targets. The average target is $359.33, accompanied by a high estimate of $394.00 and a low estimate of $310.00. This upward trend is evident, with the current average reflecting a 4.59% increase from the previous average price target of $343.56.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722539158_0.png" alt="price target chart" /></p>
<h2>Breaking Down Analyst Ratings: A Detailed Examination</h2>
<p>In examining recent analyst actions, we gain insights into how financial experts perceive Trane Technologies. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$394.00</td>
<td>$385.00</td>
</tr>
<tr>
<td>Deane Dray</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$350.00</td>
<td>$334.00</td>
</tr>
<tr>
<td>Gabe Hajde</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$315.00</td>
<td>$310.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$365.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Timothy Wojs</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$360.00</td>
<td>$344.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$385.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Gabe Hajde</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$310.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>Julian Mitchell</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$380.00</td>
<td>$354.00</td>
</tr>
<tr>
<td>Markus Mittermaier</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$375.00</td>
<td>$330.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Trane Technologies. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Trane Technologies compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Trane Technologies's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Trane Technologies's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Trane Technologies analyst ratings.</strong></a></p>
<h2>About Trane Technologies</h2>
<p>Trane Technologies manufactures and services commercial and residential HVAC systems and transportation refrigeration solutions under its prominent Trane, American Standard, and Thermo King brands. The $18 billion company generates approximately 70% of sales from equipment and 30% from parts and services. While the firm is domiciled in Ireland, North America accounts for over 70% of its revenue.</p>
<h3>Understanding the Numbers: Trane Technologies's Finances</h3>
<p><strong>Market Capitalization:</strong> Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Trane Technologies showcased positive performance, achieving a revenue growth rate of <strong>15.0%</strong> as of 31 March, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Industrials sector.</p>
<p><strong>Net Margin:</strong> Trane Technologies's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>10.35%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Trane Technologies's ROE is below industry averages, indicating potential challenges in efficiently utilizing equity capital. With an ROE of <strong>6.28%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Return on Assets (ROA):</strong> Trane Technologies's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>2.25%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Trane Technologies's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>0.71</strong>.</p>
<h2>Understanding the Relevance of Analyst Ratings</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


A Closer Look at 9 Analyst Recommendations For Trane Technologies

<p>Macquarie  analyst Paul Golding   maintains Norwegian Cruise Line (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) with a Outperform and raises the price target from $23 to $24.</p>


Price Target

NCLH

Macquarie Maintains Outperform on Norwegian Cruise Line, Raises Price Target to $24

<p><strong>Dogwifhat's </strong>(CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">WIF</a>) 20% plunge has traders wondering whether the "<a href="https://www.benzinga.com/money/what-is-dogwifhat-wif">hat has to come off</a>." </p>
<p><strong>What Happened: </strong>Crypto trader<strong> DocXBT</strong> <a href="https://x.com/docXBT/status/1818955964764098853">noted</a> that Dogwifhat has lost the trend and when such great setups fail, he chooses to not step in. While he suggests having patience currently, he thinks WIF will thrive again in a few months.</p>
<p>Another trader reacted to WIF's drop, saying it is "burn time for the dog." He predicts a plunge below $2.</p>
<p><figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"><br />
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true"><p lang="en" dir="ltr"><a href="https://twitter.com/search?q=%24WIF&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$WIF</a><br /><br />Squeaky bum time for the dog on sol again <br /><br />Wouldn&#39;t be surprised if we seen a flush below $2 again before running it back <a href="https://t.co/E7BX4deV6O">pic.twitter.com/E7BX4deV6O</a></p>
<p>&mdash; Posty (@PostyXBT) <a href="https://twitter.com/PostyXBT/status/1818573966790873532?ref_src=twsrc%5Etfw">July 31, 2024</a></p></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
<p></p></figure></p>
<p>Crypto trader Bluntz Capital in his latest <a href="https://x.com/docXBT/status/1818955964764098853">X</a> post noted a &#8220;nice move&#8221; on WIF. However, it is not an impulse to rise from the lows. He concluded, "the hat has to come off again unfortunately sorry WIF gang will try again later."</p>
<p><strong>Also Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39599028/what-is-going-on-with-shiba-inu-killer-dogwifhat">What Is Going On With &#8216;Shiba Inu Killer&#8217; Dogwifhat?</a></strong></p>
<p><strong>Why It Matters: </strong>Dogwifhat is currently 19.7% down in the past 24 hours, making it the biggest loser on the meme coin board. This takes WIF's past seven-day gains to 23.4%.</p>
<p>Coinglass data shows WIF liquidations spiked to $3.14 million in the past 24 hours, the highest since July 3.</p>
<p>In early July, a crypto trader <a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39691430/dogwifhat-pepe-will-do-what-shiba-inu-did-in-2021-and-run-to-multi-billions-predicts-trade">drew parallels</a> to Dogwifhat's performance with Shiba Inu&#8217; in the r&#8217;s run-up in 2021. The pattern followed is the run-up to billions, a retrace of the bulk of the move (-80%), and consolidation in a huge range (+/- 50%) for months.</p>
<p><strong>What&#8217;s Next</strong>: The influence of meme coins and <a href="https://www.benzinga.com/money/is-bitcoin-a-good-investment" target="_blank" rel="noreferrer noopener">Bitcoin as an institutional asset class</a> is expected to be thoroughly explored at Benzinga&#8217;s upcoming <a href="https://www.benzinga.com/events/digital-assets/agenda/" target="_blank" rel="noreferrer noopener">Future of Digital Assets</a> event on Nov. 19.</p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/markets/cryptocurrency/24/07/39691430/dogwifhat-pepe-will-do-what-shiba-inu-did-in-2021-and-run-to-multi-billions-predicts-trade">Dogwifhat, Pepe Will Do What Shiba Inu Did In 2021 And Run To Multi-Billions, Predicts Trader</a></strong></li>
</ul>
<p><em>Image: Shutterstock</em></p>


Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$WIF

Dogwifhat Down 20% And The 'Hat Has To Come Off Again,' Says Trader: 'Flush Below $2' Next?

<p>During the last three months, 14 analysts shared their evaluations of Tenable Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TENB#NASDAQ">TENB</a>), revealing diverse outlooks from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;"><strong>Bullish</strong></th>
<th style="text-align: right;"><strong>Somewhat Bullish</strong></th>
<th style="text-align: right;"><strong>Indifferent</strong></th>
<th style="text-align: right;"><strong>Somewhat Bearish</strong></th>
<th style="text-align: right;"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td style="text-align: right;">6</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">4</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for Tenable Holdings, presenting an average target of $52.29, a high estimate of $62.00, and a low estimate of $40.00. A decline of 8.63% from the prior average price target is evident in the current average. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722539033_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Tenable Holdings by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Lowers</td>
<td>Sector Perform</td>
<td>$44.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Saket Kalia</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$49.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Rob Owens</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$55.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Lowers</td>
<td>Buy</td>
<td>$52.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Michael Walkley</td>
<td>Canaccord Genuity</td>
<td>Lowers</td>
<td>Buy</td>
<td>$53.00</td>
<td>$57.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$50.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Buy</td>
<td>$55.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Shyam Patil</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Positive</td>
<td>$48.00</td>
<td>$60.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$53.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$56.00</td>
</tr>
<tr>
<td>Casey Ryan</td>
<td>WestPark Capital</td>
<td>Maintains</td>
<td>Buy</td>
<td>$54.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Shrenik Kothari</td>
<td>Baird</td>
<td>Announces</td>
<td>Outperform</td>
<td>$55.00</td>
<td>-</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Maintains</td>
<td>Buy</td>
<td>$62.00</td>
<td>$62.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Tenable Holdings. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Tenable Holdings compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts provide insights into price targets, offering estimates for the future value of Tenable Holdings's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Capture valuable insights into Tenable Holdings's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/TENB/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Tenable Holdings analyst ratings.</strong></a></p>
<h2>All You Need to Know About Tenable Holdings</h2>
<p>Founded in 2002, Tenable is a cybersecurity company that began providing vulnerability management solutions under its Nessus software. In recent years, Tenable has expanded its portfolio to provide a broader range of exposure management modules. Solutions include cloud security and compliance, active directory management, operational technology security and advanced vulnerability analytics. The Maryland-based company went public in 2018.</p>
<h3>Tenable Holdings: A Financial Overview</h3>
<p><strong>Market Capitalization Analysis:</strong> Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Tenable Holdings displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately <strong>14.36%</strong>. This indicates a notable increase in the company's top-line earnings. When compared to others in the Information Technology sector, the company faces challenges, achieving a growth rate lower than the average among peers.</p>
<p><strong>Net Margin:</strong> Tenable Holdings's net margin is below industry standards, pointing towards difficulties in achieving strong profitability. With a net margin of <strong>-6.66%,</strong> the company may encounter challenges in effective cost control.</p>
<p><strong>Return on Equity (ROE):</strong> Tenable Holdings's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of <strong>-4.08%,</strong> the company may face hurdles in generating optimal returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Tenable Holdings's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of <strong>-0.91%,</strong> the company may face hurdles in generating optimal returns from its assets.</p>
<p><strong>Debt Management:</strong> Tenable Holdings's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of <strong>1.14</strong>.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.</p>
<p>Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p>If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


TENB

Where Tenable Holdings Stands With Analysts

<p>Over the past 24 hours, <strong>Polkadot's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/dot/usd">DOT</a>) price has fallen 6.91% to <strong>$5.12</strong>. This continues its negative trend over the past week where it has experienced a 9.0% loss, moving from $5.62 to its current price. </p>
<p>The chart below compares the price movement and volatility for Polkadot over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722539022_0.png" alt="price_chart" /></p>
<p>Polkadot's trading volume has climbed 5.0% over the past week, moving in tandem, directionally, with the overall circulating supply of the coin, which has increased 0.88%. This brings the circulating supply to 1.39 billion. According to our data, the current market cap ranking for DOT is #18 at $7.13 billion.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722539022_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


Movers

$DOT

Polkadot Falls More Than 6% In 24 hours

<p>Former <strong>CNN</strong> host <strong>Don Lemon</strong> has sued the billionaire owner of <strong>X</strong>, <strong>Elon Musk,</strong> over Musk&#8217;s cancelation of Lemon&#8217;s show on <a href="https://www.benzinga.com/topic/x">the social media platform</a> last year.</p>
<p><strong>What Happened:</strong> Lemon filed the lawsuit against Musk and X on Thursday, citing the &#8220;false promises&#8221; made by Musk, <a href="https://www.washingtonpost.com/business/2024/08/01/don-lemon-elon-musk-lawsuit-x/">according</a> to the Washington Post. </p>
<p>"Executives used Don to prop up their advertising sales pitch, then canceled their partnership and dragged Don's name through the mud," Lemon's attorney, <strong>Carney Shegerian</strong>, told the Post. "Don is an accomplished and hard-hitting journalist who's committed to defending his good name and holding X's executives accountable."</p>
<p>The lawsuit alleges that Musk agreed to pay Lemon $1.5 million to make videos exclusively on X for one year. Lemon then spent hundreds of thousands of dollars to create his own media company and hire production staff.</p>
<p>Lemon&#8217;s first episode of his show featured an interview with Musk. The <strong>Tesla</strong> <strong>Inc</strong> CEO, who rarely does interviews with journalists, expressed dissatisfaction with Lemon&#8217;s line of questioning. Lemon asked questions about Musk&#8217;s involvement in politics, business decisions and <a href="https://www.benzinga.com/news/24/05/38907748/days-after-facing-lawsuit-for-drug-use-musk-says-he-would-take-cocaine-if-it-boosted-long-term-produ">frequent drug use</a>.</p>
<p>Musk then terminated the planned partnership with Lemon. Lemon was later told that he wouldn't be paid the agreed sum because there was no signed agreement, "despite Musk previously representing to Lemon that there would be no need for a formal written agreement or to &#8216;fill out paperwork,'&#8221; the lawsuit alleges.</p>
<p>Lemon&#8217;s subsequent episodes <a href="https://www.benzinga.com/news/24/04/38043705/don-lemon-show-views-tank-by-over-90-after-elon-musk-interview-on-x-platform">received little attention </a>compared to his Musk interview.</p>
<p>Musk cited the format of Lemon&#8217;s show as the rationale for not picking it up for a long-term deal.</p>
<p>&#8220;His approach was basically just &#8216;CNN, but on social media&#8217;, which doesn't work, as evidenced by the fact that CNN is dying,&#8221; Musk <a href="https://x.com/elonmusk/status/1767961809967829154">posted</a> on X. <a href="https://www.benzinga.com/news/23/04/31963594/chaos-in-cable-news-as-cnns-don-lemon-gets-fired-and-tucker-carlson-parts-ways-with-fox">CNN fired Lemon</a> in 2023.</p>
<p>Reporting by the New York Post contradicted Lemon&#8217;s account. The <a href="https://www.benzinga.com/news/24/03/37764289/elon-musk-reacts-after-ex-cnn-anchor-allegedly-demanded-tesla-cybertruck-5m-cash-stake-in-x-and-much">conservative-leaning newspaper</a> alleged that Lemon requested a Tesla Cybertruck, $5 million and an equity stake in X to host the exclusive show.</p>
<p><strong>Also Read:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/news/24/08/40091775/tesla-ceo-elon-musk-says-warren-buffett-backed-ev-maker-byd-should-change-approach-to-autonomy-fast">Tesla CEO Elon Musk Says Warren Buffett-Backed EV Maker BYD Should Change Approach To Autonomy &#8216;Fast Or They&#8217;re In Trouble&#8217;</a></strong></li>
</ul>
<p><em>Photos via Shutterstock.</em></p>


Politics

Legal

Tech

Media

Don Lemon Sues Elon Musk Over Canceled X Talk Show: Musk Used 'False Promises,' Lawsuit Alleges

WIIM

RUSHA

Rush Enterprises shares are trading higher after the company reported better-than-expected Q2 financial results.

<p><strong>Chainlink's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/link/usd">LINK</a>) price has decreased 6.64% over the past 24 hours to <strong>$12.24</strong>, continuing its downward trend over the past week of -2.0%, moving from $12.6 to its current price. </p>
<p>The chart below compares the price movement and volatility for Chainlink over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722538953_0.png" alt="price_chart" /></p>
<p>The trading volume for the coin has fallen 14.0% over the past week which is opposite, directionally, with the overall circulating supply of the coin, which has increased 0.51%. This brings the circulating supply to 608.10 million, which makes up an estimated 60.81% of its max supply of 1.00 billion. According to our data, the current market cap ranking for LINK is #17 at $7.42 billion.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722538953_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


$LINK

Chainlink Falls More Than 6% In 24 hours

<p><strong>Lido Staked Ether's</strong> (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">STETH</a>) price has decreased 6.81% over the past 24 hours to <strong>$3,088.83</strong>, continuing its downward trend over the past week of -0.0%, moving from $3,113.26 to its current price. </p>
<p>The chart below compares the price movement and volatility for Lido Staked Ether over the past 24 hours (left) to its price movement over the past week (right). The gray bands are Bollinger Bands, measuring the volatility for both the daily and weekly price movements. The wider the bands are, or the larger the gray area is at any given moment, the larger the volatility.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722538944_0.png" alt="price_chart" /></p>
<p>The trading volume for the coin has fallen 48.0% over the past week which is opposite, directionally, with the overall circulating supply of the coin, which has increased 0.5%. This brings the circulating supply to 9.84 million. According to our data, the current market cap ranking for STETH is #8 at $30.35 billion.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1722538944_1.png" alt="supply_and_vol" /></p>
<p><a href="https://www.coingecko.com/en/api">Powered by CoinGecko API</a></p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

Medinotec

News

Latest news for Medinotec (OTC:MDNC) Stock